

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
GPT Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results of GPT Healthcare Limited (the "Company") for the quarter ended September 30, 2024 and year to date from April 1, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# **S.R. BATLIBOI & Co. LLP**

Chartered Accountants

5. The comparative financial statements/information of the Company for the year ended March 31, 2024 included in these financial results were audited by the predecessor auditor who expressed an unmodified opinion on those financial statements/information on May 21, 2024. The comparative financial information of the Company for the corresponding quarter ended September 30, 2023 and six months period ended September 30, 2023, included in these financial results, have not been subject to review or audit and presented solely based on the information compiled by the management.

**For S.R. BATLIBOI & Co. LLP**

Chartered Accountants

**ICAI Firm registration number: 301003E/E300005**

  
\_\_\_\_\_

Partner

Membership No.: 060352

UDIN: 24060352BKFTGR4798

Place: Kolkata

Date: November 14, 2024



## GPT HEALTHCARE LIMITED


Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India  
CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in



### Statement Of Unaudited Financial Results for the quarter and half year ended September 30, 2024

Particulars		(₹ in lakhs unless otherwise stated)					
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited*	Unaudited	Unaudited*	Audited
1	<b>Income</b>						
	(a) Revenue from operations	10,566.28	9,781.98	10,797.51	20,348.26	20,417.56	40,019.30
	(b) Other income	280.44	223.61	108.72	504.05	252.10	529.14
	<b>Total Income</b>	<b>10,846.72</b>	<b>10,005.59</b>	<b>10,906.23</b>	<b>20,852.31</b>	<b>20,669.66</b>	<b>40,548.44</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	2,032.00	1,834.19	2,238.87	3,866.19	4,247.86	8,296.24
	(b) Employee benefits expense	1,773.38	1,871.98	1,744.23	3,645.36	3,467.51	6,893.47
	(c) Finance costs	74.03	86.01	181.44	160.04	382.05	710.50
	(d) Depreciation and amortisation expense	480.06	468.31	438.54	948.37	872.21	1,798.19
	(e) Other expenses	4,418.45	4,278.21	4,354.55	8,696.66	8,335.87	16,045.70
	<b>Total Expenses</b>	<b>8,777.92</b>	<b>8,538.70</b>	<b>8,957.63</b>	<b>17,316.62</b>	<b>17,305.50</b>	<b>33,744.10</b>
3	<b>Profit before tax (1-2)</b>	<b>2,068.80</b>	<b>1,466.89</b>	<b>1,948.60</b>	<b>3,535.69</b>	<b>3,364.16</b>	<b>6,804.34</b>
4	<b>Tax Expense</b>						
	(a) Current tax	370.00	259.00	340.00	629.00	587.00	1,189.00
	(b) Deferred tax (including MAT Credit utilisation)	216.69	211.44	258.30	428.13	428.89	838.44
	<b>Total tax expenses</b>	<b>586.69</b>	<b>470.44</b>	<b>598.30</b>	<b>1,057.13</b>	<b>1,015.89</b>	<b>2,027.44</b>
5	<b>Profit after tax (3-4)</b>	<b>1,482.11</b>	<b>996.45</b>	<b>1,350.30</b>	<b>2,478.56</b>	<b>2,348.27</b>	<b>4,776.90</b>
6	<b>Other Comprehensive Income/ (Loss) (OCI)</b>						
	Items that will not be reclassified to profit or loss						
	(i) Remeasurement of defined benefit plan	0.57	0.40	5.04	0.97	(30.27)	2.26
	(ii) Income tax relating to above	(0.16)	(0.12)	(1.46)	(0.28)	8.82	(0.66)
	<b>Other Comprehensive Income/ (Loss)</b>	<b>0.41</b>	<b>0.28</b>	<b>3.58</b>	<b>0.69</b>	<b>(21.45)</b>	<b>1.60</b>
7	<b>Total Comprehensive Income (5+6)</b>	<b>1,482.52</b>	<b>996.73</b>	<b>1,353.88</b>	<b>2,479.25</b>	<b>2,326.82</b>	<b>4,778.50</b>
8	<b>Paid up equity share capital (face value of ₹10 each) [Refer Note No 4]</b>	<b>8,205.48</b>	<b>8,205.48</b>	<b>7,990.43</b>	<b>8,205.48</b>	<b>7,990.43</b>	<b>8,205.48</b>
9	<b>Other Equity</b>						<b>13,643.55</b>
10	<b>Earnings per equity share (of ₹10 each) :</b>						
	(a) Basic (₹)	1.81**	1.21**	1.69**	3.02**	2.94**	5.96
	(b) Diluted (₹)	1.81**	1.21**	1.69**	3.02**	2.94**	5.96

\*Refer Note No 6 of the accompanying notes to Unaudited Financial Results  
The figures marked with (\*\*) are not annualised




## GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India  
CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in

### Statement of Unaudited Assets and Liabilities as at September 30, 2024

(₹ in lakhs)

Particulars	As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
<b>ASSETS</b>		
<b>A) Non-Current Assets</b>		
(a) Property, Plant and Equipment	19,869.97	20,106.83
(b) Capital work-in-progress	1,336.75	639.97
(c) Intangibles Assets	124.97	84.69
(d) Right of Use Assets	2,187.84	2,213.71
<b>(e) Financial Assets</b>		
(i) Investments	2,293.01	1,916.92
(ii) Loans	6.83	5.29
(iii) Other Financial Assets	1,230.40	972.82
(f) Non Current Tax (Net)	399.84	528.94
(g) Other Non Current Assets	249.08	66.98
<b>Total Non-Current Assets</b>	<b>27,698.69</b>	<b>26,536.15</b>
<b>B) Current Assets</b>		
(a) Inventories	910.67	815.49
<b>(b) Financial Assets</b>		
(i) Investments	1,601.49	1,118.05
(ii) Trade receivable	2,816.52	2,428.48
(iii) Cash and cash equivalents	324.52	169.32
(iv) Bank balances other than (iii) above	128.13	743.70
(v) Loans	76.95	1,121.75
(vi) Other Financial Assets	786.37	1,462.62
(c) Other Current Assets	331.45	156.29
<b>Total Current Assets</b>	<b>6,976.10</b>	<b>8,015.70</b>
<b>Total Assets</b>	<b>34,674.79</b>	<b>34,551.85</b>
<b>EQUITY AND LIABILITIES</b>		
<b>C) Equity</b>		
(a) Equity Share Capital	8,205.48	8,205.48
(b) Other Equity	14,891.98	13,643.55
<b>Total Equity</b>	<b>23,097.46</b>	<b>21,849.03</b>
<b>Liabilities</b>		
<b>D) Non-current Liabilities</b>		
<b>(a) Financial Liabilities</b>		
(i) Borrowings	228.38	362.40
(ii) Lease Liabilities	1,542.86	1,534.94
(b) Provisions	709.53	754.52
(c) Deferred Tax Liabilities (Net)	1,624.36	1,195.95
(d) Other Non Current Liabilities	1,101.96	1,134.20
<b>Total Non-current Liabilities</b>	<b>5,207.09</b>	<b>4,982.01</b>
<b>E) Current Liabilities</b>		
<b>(a) Financial liabilities</b>		
(i) Borrowings	687.61	879.66
(ii) Lease Liabilities	330.27	277.32
(iii) Trade payables		
-Total outstanding dues to micro enterprises and small enterprises	330.61	291.93
-Total outstanding dues to other than micro enterprises and small enterprises	3,346.43	3,446.92
(iv) Other Financial Liabilities	927.57	2,007.34
(b) Other Current Liabilities	523.15	702.05
(c) Provisions	224.60	115.59
<b>Total Current Liabilities</b>	<b>6,370.24</b>	<b>7,720.81</b>
<b>Total Liabilities</b>	<b>11,577.33</b>	<b>12,702.82</b>
<b>Total Equity &amp; Liabilities</b>	<b>34,674.79</b>	<b>34,551.85</b>



## GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India  
CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in

### Statement of Unaudited Cash Flows for the half year ended September 30, 2024

(₹ in lakhs)

Particulars	For the half year ended September 30, 2024 (Unaudited)	For the half year ended September 30, 2023 (Unaudited)*
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit Before Tax	3,535.69	3,364.16
<u>Adjustment to reconcile profit before tax to net cash flows</u>		
(a) Depreciation and Amortisation Expense	948.37	872.21
(b) Finance Costs	160.04	382.05
(c) Profit on sale/fair value of Investments (net)	(32.84)	(9.52)
(d) Capital Work-in Progress written off	-	28.50
(e) Liabilities no longer required written back	(84.70)	(16.69)
(f) Bad debts	131.03	-
(g) Provision for Doubtful Trade Receivables	62.84	89.44
(h) Gain on retirement of Right of Use Assets	(14.83)	(38.58)
(i) Deferred Revenue on Government Grant	(32.23)	(32.23)
(j) Profit on sale of Property, plant & equipment	(14.66)	-
(k) Interest Income	(246.54)	(167.70)
Cash Generated from operations before working capital changes	4,412.17	4,471.64
<u>Adjustments for working capital changes :</u>		
(a) (Increase) in Inventories	(95.18)	(66.58)
(b) (Increase) in Trade Receivables	(581.90)	(821.41)
(c) (Increase)/ decrease in Other Financial Assets	558.90	(131.26)
(d) (Increase) in Non-Financial Assets	(171.95)	(51.60)
(e) Increase/ (decrease) in Trade Payables	(39.85)	752.01
(f) Increase/ (decrease) in Other Financial Liabilities	(1,041.98)	14.66
(g) Increase in Provisions	82.56	68.15
(h) (Decrease) in Non-financial liabilities	(178.90)	(276.54)
Cash Generated from Operations	2,943.87	3,959.07
Direct Taxes Paid (net of refund)	(473.88)	(559.33)
<b>Net Cash generated from Operating Activities (A)</b>	<b>2,469.99</b>	<b>3,399.74</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
(a) Purchase of Investments	(1,488.67)	(700.00)
(b) Purchase of Property, Plant & Equipment & Intangible Assets (Including Capital Work-in-Progress)	(1,391.74)	(1,147.17)
(c) Proceeds from sale of Property, Plant & Equipment	43.56	-
(d) Proceeds from sale of Investments	638.42	409.00
(e) Payment towards acquisition of ROU Assets	-	(31.64)
(f) Proceeds from maturity of deposits	611.74	-
(g) Deposits made	(200.00)	(125.10)
(h) Loan Refund received from Body Corporates	1,044.30	702.13
(i) Interest Received	297.11	258.51
<b>Net Cash used in Investing Activities (B)</b>	<b>(445.28)</b>	<b>(634.27)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
(a) Dividend paid	(1,230.82)	(1,598.09)
(b) Interest Paid	(72.44)	(271.70)
(c) Repayment of Long Term and Short Term Borrowings	(499.86)	(1,047.67)
(d) Proceeds from Short Term Borrowings	191.00	-
(e) Cash Credit (repaid)/taken (net)	(17.77)	129.07
(f) Payment of principal portion of lease liabilities	(239.62)	(210.00)
<b>Net Cash used in Financing Activities (C)</b>	<b>(1,869.51)</b>	<b>(2,998.39)</b>
Net increase/(decrease) in Cash & Cash Equivalent (A+B+C)	155.20	(232.92)
Cash & Cash Equivalents at the beginning of the period	169.32	659.93
Cash & Cash Equivalents at the end of the period	<b>324.52</b>	<b>427.01</b>

\*Refer Note No 6 of the accompanying notes to Unaudited Financial Results



**Notes:**

1. The above unaudited financial results of the Company for the quarter and half year ended September 30, 2024 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on November 14, 2024. These unaudited financial results have been subjected to limited review by the statutory auditors of the Company in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") who has issued an unmodified conclusion on these unaudited financial results.
2. The unaudited financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
3. The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India.
4. During the year ended March 31, 2024, GPT Healthcare Limited ("the Company") has completed Initial Public Offering (IPO) comprising of fresh issue of 21,50,537 equity shares and offer for sale from investor selling shareholder of 2,60,82,786 equity shares of face value ₹10 each at an issue price of ₹186 per share for cash consideration aggregating to ₹52,513.98 Lakhs. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange w.e.f. February 29, 2024.
5. The Board of Directors at its meeting held on November 14, 2024, declared an Interim Dividend of 10% i.e Re.1/- per equity share of Rs. 10/- each fully paid up. The Company has fixed November 28, 2024, as the Record Date for the purpose of determining shareholders entitled to receive the said Interim Dividend.
6. The financial results and other financial information for the quarter and half year ended September 30, 2023 and statement of cash flow for the half year ended September 30, 2023 have not been audited or reviewed by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs.
7. The above unaudited financial results are also available on the Company's website [www.ilshospitals.com](http://www.ilshospitals.com) and also on the stock exchange websites.



For and on behalf of the Board of Directors

Dwarika Prasad Tantia  
Executive Chairman  
DIN : 00001341



Place : Kolkata  
Date : November 14, 2024